WASHINGTON (AP) — Columbia Laboratories said Monday that U.S. health regulators denied approval of its hormone-based gel designed to prevent premature birth. Shares of the small drugmaker plummeted more than 8 percent on the news.
The company said the Food and Drug Administration rejected the drug after concluding it did not meet the minimum standards for effectiveness required of such products. The ruling followed a public hearing last month where a panel of reproductive health doctors voted 13-4 against approval for the progesterone-based gel. The FDA is not required to follow such recommendations, though it often does.
Columbia Laboratories submitted the drug as a treatment to reduce instances of non-full-term births by women with abnormally short cervixes. The company estimates the problem affects 10 to 12 percent of all pregnancies in the U.S. and accounts for 34 percent of all infant deaths in the U.S.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
